A pharmacy-based approach to XXXX management.

@entity1 @entity65 @entity165
OBJECTIVE: To determine the clinical and economic impact of a pharmacy-based @entity165 management program in @entity1 with @entity65 . STUDY DESIGN: Demonstration project. @entity1 AND METHODS: From January 1, 1999, through June 30, 1999, 300 @entity1 with a documented history of @entity65 were enrolled in a pharmacy-based @entity165 program. A similar group of 150 randomly selected @entity1 receiving usual care during the same period served as the comparator group. The following were collected for both groups: @entity1 demographics, comorbidities, fasting lipid profiles, @entity165 medication, cost of medication, and cardiovascular events. The McNemar symmetry chi2 test was used to compare appropriate laboratory monitoring, receipt of @entity165 medication, and achievement of target low-density lipoprotein @entity165 levels at baseline and 1 year for both groups. Kruskal-Wallis analysis of variance was used to compare the cost of therapy for both groups at baseline and follow-up. RESULTS: Mean +/- SD age of program and usual care @entity1 was 67 +/- 10 and 69 +/- 11 years, respectively. At 1 year, >95% of program @entity1 were receiving appropriate laboratory monitoring. In 1 year, the percentage of @entity1 reaching target low-density lipoprotein @entity165 levels increased from 45% to 72% (P< .01) and from 33% to 43% (P = .26) in program and usual care @entity1 , respectively. Despite increased medication use among program @entity1 , their cost per @entity1 per month was lower at 1-year follow-up vs baseline. CONCLUSION: Regular @entity1 interaction and close @entity1 monitoring allowed the pharmacy-based lipid management program to improve @entity165 management in @entity1 with @entity65 .
